etx101
Gene therapyexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2022 (NCT05419492)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetSupplementation
supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06283212 | Phase 1/Phase 2 (Phase 2) | May 9, 2024 | Encoded Therapeutics |
| NCT06112275 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2024 | Encoded Therapeutics |
| NCT05419492 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | Encoded Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Encoded Therapeutics | For profit | 3 | 3 | 1 | 2022 |
1 organizations
Page 1 / 1